PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Paul-Ehrlich-Institute, IVD Testing Laboratory, Langen, Germany. Electronic address: schhe@pei.de.\', \'Paul-Ehrlich-Institute, Division Major Policy Issues, Coordination, Langen, Germany.\', \'University Hospital Frankfurt - Department of Infectious Diseases and HIV, Goethe University Frankfurt, Frankfurt am Main, Germany.\', \'University Hospital Frankfurt - Department of Respiratory Medicine and Allergology, Goethe University Frankfurt, Frankfurt am Main, Germany.\', \'University Hospital Frankfurt - Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Goethe University Frankfurt, Frankfurt am Main, Germany.\', \'Paul-Ehrlich-Institute, IVD Testing Laboratory, Langen, Germany.\', \'Paul-Ehrlich-Institute, Division Allergology, Langen, Germany.\', \'Paul-Ehrlich-Institute, Division Safety of Medicinal Products and Medical Devices, Langen, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1386-6532(21)00319-X10.1016/j.jcv.2021.105052
?:doi
?:hasPublicationType
?:journal
  • Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
is ?:pmid of
?:pmid
?:pmid
  • 34920374
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all